PDT Systems

Santa Barbara, CA 93117

SBIR Award Summary

Total Number of Awards 19
Total Value of Awards $0.0
First Award Date 05/01/86
Most Recent Award Date 09/30/95

Key Personnel

Last Name Name Awards Contact
Doiron Daniel R Doiron 17
Narciso Hugh L Narciso 2

19 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/95 - 09/29/96

Photodynamic Therapy, PDT, is presently undergoing extensive clinical trials for the diagnosis and treatment of cancer. Regulatory approval of first generation PDT drug, Photofrin, was obtained in Canada in 1993, and regulatory approval in Japan and the Netherlands is expected in 1994. Filing of an NDA for Ph...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/26/95 - 01/25/96

DESCRIPTION (Adapted from applicant's abstract): This is a Phase I program to study the effectiveness of ethyletiopurpurin (SnET2) and octaethylbenzochlorin iminium salt (BCIS1) photosynthesizers and photodynamic therapy (PDT) in the treatment of refractory glaucoma. During the program, the...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 03/01/95 - 08/31/95

The two main clinical dysfunctions of the prostate are benign prostatic hypertrophy and malignant disease. A number of innovative approaches to treat these diseases have been introduced over the last decade to try and replace the TURP and intraoperative surgical approaches. These include pharmacological manipulation through alpha-blockers, b...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/94 - 09/29/95

Photodynamic Therapy, PDT, is presently undergoing extensive clinical trials for the diagnosis and treatment of cancer. Regulatory approval of first generation PDT drug, Photofrin, was obtained in Canada in 1993, and regulatory approval in Japan and the Netherlands is expected in 1994. Filing of an NDA for Photofrin for use in esophageal cancer...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/93 - 02/28/94

Interest in medical procedures such as Photodynamic Therapy (PDT), Interstitial Laser Hyperthermia (ILH), and Interstitial Laser Photocoagulation (ILP) is on the rise. Other medical procedures such as Cardiovascular-PDT (CV-PDT) and Laser Tissue Welding (LTW) are in their infancy. The one unifying parameter among these distinctly different disci...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 05/27/93 - 11/26/93

DESCRIPTION (Adapted from applicant's abstract): Photodynamic Therapy (PDT) using Photofrin is nearing regulatory approval both in the USA and abroad. It has been shown by a number of researchers that hyperthermia (HT), less than 45 degrees centrigrade, has a strong synergistic effect in combination with PDT. This synergism appears to be maxi...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/92 - 03/31/93

Photodynamic Therapy (PDT) is presently undergoing extensive basic, preclinical and clinical testing for the diagnosis and treatment of cancer. Regulatory approval for the first PDT drug or photosensitizer, Photofrin, is expected in 1993. Concurrent with this is the introduction of a number of second generation photosensitizers into clinical tr...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/92 - 02/28/93

DESCRIPTION (Adapted from applicant's abstract):Photodynamic Therapy (PDT) is presently undergoing extensive basic, pre-clinical, and clinical investigation for the diagnosis and treatment of cancer.The majority of this work has involved various versions of Hematoporphyrin Derivative (HpD) with the most recent purified version, Dihematoporphyrin...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/91 - 03/29/93

Photodynamic therapy (PDT) is continuing to undergo a rapid expansion in basic, preclinical and clinical research, and development as a modality for the diagnosis and treatment of cancer and other nonmalignant diseases. One of the major hindrances to this development is the lack of an efficient, reliable and easy to use laser source. In additi...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/18/91 - 06/30/92

Photodynamic therapy, PDT, is presently undergoing extensive basic, preclinical and clinical testing for the diagnosis and treatment of cancer. Regulatory approval for the first PDT drug, Photofrin-II is expected in late 1991. Concurrent with this is the introduction of a number of second generation PDT drugs into clinical trials. all of these...

Load More